Koyfin Home > Directory > Health Care > Rigel Pharmaceuticals > EBITDA

Rigel Pharmaceuticals EBITDA Chart (RIGL)

Rigel Pharmaceuticals annual/quarterly EBITDA from 2010 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Rigel Pharmaceuticals EBITDA for the quarter ending June 06, 2020 was $-17m a 31.09% decrease of -5m year over year
  • Rigel Pharmaceuticals EBITDA for the last 12 months ending June 06, 2020 was $-25m a -93.77% increase of 23m year over year
  • Rigel Pharmaceuticals Annual EBITDA for 2019 was $-68m a -5.38% increase of 4m from 2018
  • Rigel Pharmaceuticals Annual EBITDA for 2018 was $-72m a -9.80% increase of 7m from 2017
  • Rigel Pharmaceuticals Annual EBITDA for 2017 was $-79m a 20.37% decrease of -16m from 2016
Other Income Statement Metrics:
  • Rigel Pharmaceuticals Net Income for the quarter ending December 12, 2018 was $3m a 855.42% increase of 28m year over year
  • Rigel Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $5m a 26.33% increase of 1m year over year
View Chart On Koyfin

Quarterly RIGL EBITDA Data

06/2020$-17m
03/2020$21m
12/2019$-17m
09/2019$-12m
06/2019$-21m
03/2019$-18m
12/2018$3m
09/2018$-24m
06/2018$-26m
03/2018$-25m

Annual RIGL EBITDA Data

2019$-68m
2018$-72m
2017$-79m
2016$-63m
2015$-50m
2014$-89m
2013$-85m
2012$-97m
2011$-84m
2010$37m